Abaloparatide (Tymlos)

FDA-approved product existsPeptideRecovery & tissue repair

Awaiting review, BioHarmony verdict

Not yet scored. Queued for review; until then rely on the status and sources below.

What is Abaloparatide (Tymlos)?

FDA-approved abaloparatide is marketed as Tymlos for specified women and men with osteoporosis at high fracture risk or who have failed or cannot tolerate other therapy.

Saved on this device only.

Dosing as published

Source-reported figures only. This page does not calculate a personal dose.

Approved labelTYMLOS prescribing information for approved osteoporosis indications
PopulationWomen and men covered by the approved TYMLOS indications
Dose80 mcg
RouteSubcutaneous injection into the periumbilical abdomen
FrequencyOnce daily at approximately the same time each day
DurationThe label states that safety and effectiveness beyond 2 years have not been evaluated and use beyond 2 years during a lifetime is not recommended
PreparationReady-to-use 3120 mcg/1.56 mL solution in a prefilled pen delivering thirty 80 mcg doses; no reconstitution.
Source: Dosage and Administration sections 2.1-2.3; Dosage Forms and Strengths section 3

Working with a vial? The reconstitution calculator covers mixing math, not dosing advice.

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Trust & sourcing

  1. Last revieweddone
  2. Next reviewupcoming
US approvalFDA-approved product exists
CompoundingFDA-approved product exists; compounded copies are not FDA approved

Primary sources

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.